Search Result

Results for "

HIV+Integrase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HIV Integrase (24) Biochemical Assay Reagents (1) Drug Derivative (1) Drug Metabolite (1) HIV (20) Isotope-Labeled Compounds (8) OAT (3) Reference Standards (4) UGT (1)
By Research Areas:	Infection (26) Metabolic Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: HIV Integrase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13238

Dolutegravir Maximum Cited Publications 32 Publications Verification S/GSK1349572	HIV Integrase HIV	Infection
Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

HY-14740

Elvitegravir 10+ Cited Publications GS-9137; JTK-303; D06677	HIV Integrase HIV	Infection
Elvitegravir (GS-9137; JTK-303; D06677) is an *HIV integrase* inhibitor for HIV-1_IIIB, HIV-2_EHO and HIV-2_ROD with IC₅₀ of 0.7 nM, 2.8 nM and 1.4 nM, respectively.

HY-15592

Cabotegravir 10+ Cited Publications GSK-1265744; S/GSK1265744	OAT HIV HIV Integrase	Infection
Cabotegravir (GSK-1265744) is a orally active and long-acting *HIV integrase* strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC₅₀ values of 2.5 nM, 0.41 μM and 0.81 μM for HIV_ADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS .

HY-111832

1,2,3,6-Tetragalloylglucose TeGG	UGT	Infection Metabolic Disease
1,2,3,6-Tetragalloylglucose (TEgG) is a competitive inhibitor of UDP-glucuronyltransferase UGT1A1, targeting the competitive substrate binding site of UGT1A1. 1,2,3,6-Tetragalloylglucose inhibits UGT1A1-mediated β-estradiol 3-glucuronidation and SN-38 glucuronidation with IC₅₀ of 6.01 μM and 4.31 μM, respectively, and binds to UGT1A1 with K_i of 3.55 μM. 1,2,3,6-Tetragalloylglucose also induces tumor cell apoptosis, inhibit cell proliferation, activates caspase-3 and induces DNA fragmentation in HL-60 cells. 1,2,3,6-Tetragalloylglucose also inhibits *HIV integrase* and reverse transcriptase, and inhibits HCV protease .

HY-13238A

Dolutegravir sodium Maximum Cited Publications 32 Publications Verification S/GSK1349572 sodium	HIV Integrase HIV	Infection
Dolutegravir sodium (S/GSK1349572 sodium) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir sodium (S/GSK1349572 sodium) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir sodium (S/GSK1349572 sodium) retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

HY-15592A

Cabotegravir sodium 10+ Cited Publications GSK-1265744 sodium; S/GSK1265744 sodium	OAT HIV HIV Integrase	Infection
Cabotegravir (GSK-1265744) sodium is a orally active and long-acting *HIV integrase* strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC₅₀ values of 2.5 nM, 0.41 μM and 0.81 μM for HIV_ADA, OAT3 and OAT1, respectively. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir sodium can be used to research AIDS .

HY-10522

LEDGIN6 4 Publications Verification CX05168; CX04328	HIV HIV Integrase	Infection
LEDGIN6 (CX05168) is a quinoline-based protein-protein interaction inhibitor of LEDGF/p75 and *HIV integrase* .

HY-177098

Lepetegravir	HIV HIV Integrase	Infection
Lepetegravir (Example 24) is a *HIV integrase* inhibitor. Lepetegravir has antiviral effects (EC₅₀: 0.98 nM in MT-4 cells) .

HY-176960

3-Amino-2-hydroxypropyl dihydrogen phosphate	Biochemical Assay Reagents	Others
3-Amino-2-hydroxypropyl dihydrogen phosphate is a chemical modification complex of the DNA phosphate backbone, which can be used to study the interaction between HIV integrase (IN) and DNA .

HY-15592AS

Cabotegravir-d3 sodium GSK-1265744-d3 sodium; S/GSK1265744-d3 sodium	Isotope-Labeled Compounds HIV Integrase	Infection
Cabotegravir-d₃ (sodium) is the deuterium labeled Cabotegravir sodium. Cabotegravir sodium is a highly potent HIV integrase inhibitor with an IC50 value of 2.5 nM for HIVADA. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltr

HY-177071

Asuptegravir	HIV	Infection
Asuptegravir (Compound 1) is an inhibitor of *HIV* integrase activity. Asuptegravir inhibits HIV in HEK293T cells (EC₅₀ = 1.08 nM). Asuptegravir can be studied in anti-AIDs/HIV research .

HY-117879

PF-4776548	HIV HIV Integrase	Infection
PF-4776548 is a highly potent *HIV integrase* inhibitor. PF-477654 blocks the process of integrating HIV viral DNA into the host cell genome. PF-4776548 is promising for research of AIDS .

HY-14740R

Elvitegravir (Standard) GS-9137 (Standard); JTK-303 (Standard); D06677 (Standard)	Reference Standards HIV Integrase HIV	Infection
Elvitegravir (Standard) is the analytical standard of Elvitegravir. This product is intended for research and analytical applications. Elvitegravir (GS-9137; JTK-303; D06677) is an *HIV integrase* inhibitor for HIV-1_IIIB, HIV-2_EHO and HIV-2_ROD with IC₅₀ of 0.7 nM, 2.8 nM and 1.4 nM, respectively.

HY-15592R

Cabotegravir (Standard) GSK-1265744 (Standard); S/GSK1265744 (Standard)	OAT Reference Standards HIV HIV Integrase	Infection
Cabotegravir (Standard) is the analytical standard of Cabotegravir. This product is intended for research and analytical applications. Cabotegravir (GSK-1265744) is a orally active and long-acting *HIV integrase* strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC₅₀ values of 2.5 nM, 0.41 μM and 0.81 μM for HIV_ADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS .

HY-13238S1

Dolutegravir-d3 S/GSK1349572-d₃	Isotope-Labeled Compounds HIV Integrase HIV	Infection
Dolutegravir-d₃ is the deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

HY-13238S2

Dolutegravir-d5 S/GSK1349572-d₅	Isotope-Labeled Compounds HIV Integrase HIV	Infection
Dolutegravir-d₅ is deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

HY-13238R

Dolutegravir (Standard) S/GSK1349572 (Standard)	Reference Standards HIV Integrase HIV	Infection
Dolutegravir (Standard) is the analytical standard of Dolutegravir. This product is intended for research and analytical applications. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

HY-P2379

His-Cys-Lys-Phe-Trp-Trp	HIV Integrase	Infection
His-Cys-Lys-Phe-Trp-Trp is an inhibitor for the human immunodeficiency virus (HIV) integrase with an IC₅₀ of 2 μM .

HY-W749636

N-De-2,4-difluorobenzyl dolutegravir	Drug Metabolite HIV Integrase	Infection
N-De-2,4-difluorobenzyl dolutegravir is a metabolite of Dolutegravir (HY-13238). Dolutegravir is a HIV integrase inhibitor inhibitor .

HY-15592S2

Cabotegravir-d3-1 GSK-1265744-d₃-1; S/GSK1265744-d₃-1	Isotope-Labeled Compounds HIV Integrase	Infection
Cabotegravir d3-1 (GSK-1265744-d3-1) is a deuterium substitute of Cabotegravir. Cabotegravir is a potent *HIV integrase* inhibitor used in AIDS research

HY-14740S

Elvitegravir-d8 GS-9137-d₈; JTK-303-d₈; D06677-d₈	Isotope-Labeled Compounds HIV Integrase HIV	Infection
Elvitegravir-d₈ is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.

HY-14740S2

Elvitegravir-13C6 GS-9137-¹³C₆ ; JTK-303-¹³C₆ ; D06677-¹³C₆	Isotope-Labeled Compounds HIV Integrase HIV	Infection
Elvitegravir- ¹³C₆ (GS-9137- ¹³C₆) is ¹³C labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an *HIV integrase* inhibitor for HIV-1_IIIB, HIV-2_EHO and HIV-2_ROD with IC₅₀ of 0.7 nM, 2.8 nM and 1.4 nM, respectively.

HY-14740S1

Elvitegravir-d6 GS-9137-d₆; JTK-303-d₆; D06677-d₆	Isotope-Labeled Compounds HIV Integrase HIV	Infection
Elvitegravir-d₆ (GS-9137-d₆) is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an *HIV integrase* inhibitor for HIV-1_IIIB, HIV-2_EHO and HIV-2_ROD with IC₅₀ of 0.7 nM, 2.8 nM and 1.4 nM, respectively .

HY-W876243

Averionol	Drug Derivative HIV Integrase	Infection
Averionol (Compound 26) is a flavonoid compound. Averionol has no significant inhibitory activity against *HIV integrase*. Averionol can be used in the development of anti-HIV agents .

HY-185448

HIV RT-IN-1	HIV HIV Integrase	Infection
HIV RT-IN-1 is an inhibitor of *HIV integrase* and HIV reverse transcriptase-associated ribonuclease H. HIV RT-IN-1 is applicable to research related to HIV-1 infection .

HY-10522R

LEDGIN6 (Standard) CX05168 (Standard); CX04328 (Standard)	Reference Standards HIV HIV Integrase	Infection
LEDGIN6 (Standard) is the analytical standard of LEDGIN6 (HY-10522). This product is intended for research and analytical applications. LEDGIN6 (CX05168) is a quinoline-based protein-protein interaction inhibitor of LEDGF/p75 and HIV integrase .

HY-14740S3

Elvitegravir-d5 GS-9137-d₅; JTK-303-d₅; D06677-d₅	Isotope-Labeled Compounds HIV HIV Integrase	Infection
Elvitegravir-d₅ (GS-9137-d₅; JTK-303-d₅; D06677-d₅) is the deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an *HIV integrase* inhibitor for HIV-1_IIIB, HIV-2_EHO and HIV-2_ROD with IC₅₀ of 0.7 nM, 2.8 nM and 1.4 nM, respectively.

Cat. No.	Product Name	Target	Research Area

HY-P2379

His-Cys-Lys-Phe-Trp-Trp	HIV Integrase	Infection
His-Cys-Lys-Phe-Trp-Trp is an inhibitor for the human immunodeficiency virus (HIV) integrase with an IC₅₀ of 2 μM .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-111832

1,2,3,6-Tetragalloylglucose TeGG	other families Classification of Application Fields Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	UGT
1,2,3,6-Tetragalloylglucose (TEgG) is a competitive inhibitor of UDP-glucuronyltransferase UGT1A1, targeting the competitive substrate binding site of UGT1A1. 1,2,3,6-Tetragalloylglucose inhibits UGT1A1-mediated β-estradiol 3-glucuronidation and SN-38 glucuronidation with IC₅₀ of 6.01 μM and 4.31 μM, respectively, and binds to UGT1A1 with K_i of 3.55 μM. 1,2,3,6-Tetragalloylglucose also induces tumor cell apoptosis, inhibit cell proliferation, activates caspase-3 and induces DNA fragmentation in HL-60 cells. 1,2,3,6-Tetragalloylglucose also inhibits *HIV integrase* and reverse transcriptase, and inhibits HCV protease .

Cat. No.	Product Name	Chemical Structure

HY-15592AS

Cabotegravir-d3 sodium
Cabotegravir-d₃ (sodium) is the deuterium labeled Cabotegravir sodium. Cabotegravir sodium is a highly potent HIV integrase inhibitor with an IC50 value of 2.5 nM for HIVADA. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltr

HY-13238S1

Dolutegravir-d3
Dolutegravir-d₃ is the deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

Dolutegravir-d3

Dolutegravir-d₃ is the deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

HY-13238S2

Dolutegravir-d5
Dolutegravir-d₅ is deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

Dolutegravir-d5

Dolutegravir-d₅ is deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .